- Lobbying
- novartis
Lobbying Arrangements Results for 'Novartis'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutic... |
Novartis
|
BROWNSTEIN HYATT FARBER SCHRECK, LLP | |||
Details Implementation of Tax Reform, international tax proposals related to intellectual property. Issues related to Biosimilar Approvals and implementation of biologic price competition and innovation ac... |
NOVARTIS CORPORATION
|
CAPITOL HILL CONSULTING GROUP | |||
Details Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patient out of pocket costs, supply chain, PBM polici... |
Novartis
|
BGR Government Affairs | |||
Details Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act. Is... |
Tiber Creek Health Strategies, Inc. (On behalf of Novartis)
|
Tiber Creek Group | |||
Details Federal budget issues H.R. 5378: Lower Costs, More Transparency Act IRA implementation, 340B, affordability, pharmaceutical innovation, transparency, intellectual property, kidney care policies, P... |
Novartis
|
TARPLIN, DOWNS & YOUNG, LLC | |||
Details Supply Chain. 340B Issues. Biologics Price Competition and Innovation Act. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. Advanced Research Projects Agency for... |
Novartis, Inc.
|
Todd Strategy Group | |||
Details Medicare reimbursement issues, FDA regulation of biosimilars. |
The Biosimilars Forum
|
HOLLAND & KNIGHT LLP | |||
Details Enforcement priorities and policies regarding communications by pharmaceutical and medical device manufacturers about their medical products. |
Medical Information Working Group
|
Ropes & Gray, LLP | |||
Details Pharmaceutical distribution and supply chain security. |
Pharmaceutical Distribution Security Alliance (PDSA)
|
Leavitt Partners, LLC | |||
Details Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2010 - Funding for domestic vaccine supply, Centers for Disease Control, National Institutes... |
NOVARTIS CORP.
|
PARRY, ROMANI, DECONCINI & SYMMS | |||
Details Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Ensuring Access to Lower-Cost Medicines for Senio... |
The Biosimilars Forum
|
Thorn Run Partners | |||
Details Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of C... |
Novartis, Inc.
|
Forbes-Tate | |||
Details Drug importation; drug safety and drug counterfeiting; Authorized generics; Drug company patent settlements; Prescription drug advertising; The Promoting Life Saving New Therapies for Neonates Act;... |
NOVARTIS, INC
|
Williams and Jensen, PLLC |